{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123322","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.698090+00:00","generated_at":"2026-05-30T03:16:39.428635+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q3 revenue $35.3M (+59% YoY); raises FY revenue guidance to $139-140M","bullets":["Revenue $35.3M, up 59% YoY; LAL procedures 24,554 (+80%), LDD installed base 888 (+51%).","Gross margin 71.4% vs 61.9% YoY; net loss narrowed to $6.3M ($0.16/sh) from $12.4M ($0.35/sh).","Adjusted net earnings $214K ($0.00/diluted) vs adjusted loss $6.9M ($0.19/sh) a year ago.","FY2024 revenue guidance raised to $139-140M top of prior range; gross margin guided 70-71% (up from 68-70%).","Cash & equivalents $237.1M at Sept 30, 2024 vs $233.3M at June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123322","json":"https://secwatch.observer/filing/0000950170-24-123322.json","markdown":"https://secwatch.observer/filing/0000950170-24-123322.md","text":"https://secwatch.observer/filing/0000950170-24-123322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024123322/0000950170-24-123322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024123322/rxst-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:16:39.428635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}